GeneCentric Diagnostics' Unattributed Round

GeneCentric Diagnostics raised a round of funding on January 30, 2017. Investors include Bristol-Myers Squibb.

GeneCentric Diagnostics focuses on the development and commercialization of molecular diagnostic assays that enable oncologists and patients to make more informed, individualized treatment decisions.…

Articles about GeneCentric Diagnostics' Unattributed Round: